menu
    • menu
    [{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Not Applicable"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Cytocom","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"CYTO-200","moa":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland BioLabs","highestDevelopmentStatusID":"9","companyTruncated":"Cleveland Clinic \/ Cleveland BioLabs"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Anixa Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Cleveland Clinic \/ Anixa Biosciences"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"AriBio","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"PDE5","graph1":"Neurology","graph2":"Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic Genomic Medicine Institute","highestDevelopmentStatusID":"8","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic Genomic Medicine Institute"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Ovarian Cancer Vaccine","moa":"ED-AMHR2","graph1":"Oncology","graph2":"Preclinical","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic","highestDevelopmentStatusID":"4","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Synaptogenix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Bryostatin-1","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Synaptogenix","highestDevelopmentStatusID":"4","companyTruncated":"Cleveland Clinic \/ Synaptogenix"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Anixa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"Alpha-lactalbumin-based Vaccine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic","highestDevelopmentStatusID":"14","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"NeuroTherapia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"NTRX-07","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cleveland Clinic","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic","highestDevelopmentStatusID":"14","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic"}]

    Find Clinical Drug Pipeline Developments & Deals by Cleveland Clinic

    Menu

    Cleveland Clinic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : NeuroTherapia

                            Deal Size : $12.3 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            NeuroTherapia Raises $12.3M in the First Close of its Series B Financing

                            Details : NeuroTherapia will use this funding primarily for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer's disease

                            Brand Name : NTRX-07

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 06, 2024

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : NeuroTherapia

                            Deal Size : $12.3 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : TFF Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals and Cleveland Clinic to Advance Influenza Vaccine Candidates

                            Details : TFF collaborates with Cleveland to advance multiple multivalent universal influenza vaccines, which are being evaluated in early-stage clinical trials to protect against seasonal & pandemic viruses.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 20, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : TFF Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alpha-lactalbumin-based Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Anixa Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Anixa Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines

                            Details : Under the expanded partnership, companies will co-develop vaccines for cancers. Cleveland Clinic is conducting a Phase 1 trial for triple-negative breast cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 08, 2024

                            Lead Product(s) : Alpha-lactalbumin-based Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Anixa Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Synaptogenix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Tri...

                            Details : The agreement aims to conduct a phase 1 trial of Bryostatin-1, a small molecule that works by activating protein kinase C, in multiple sclerosis (MS).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 19, 2023

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Synaptogenix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ovarian Cancer Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Anixa Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of...

                            Details : By developing ovarian cancer vaccine that target alpha-lactalbumin and AMHR2-ED, immune system can destroy breast cancer cells and ovarian cancer cells, respectively, as they arise and ultimately prevent tumors from forming.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 12, 2022

                            Lead Product(s) : Ovarian Cancer Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Anixa Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : AriBio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            The Potential of PDE5 Inhibitors, Such as AriBio’s AR1001, the Lead Clinical Candidate for Alzheimer’s Dis...

                            Details : Positive Phase II trial reported for AR1001, the results confirmed the possibility of developing a unique oral disease-modifying treatment for AD that improves cognitive function. The Company will complete Phase III clinical trials of AR1001 within the n...

                            Brand Name : AR1001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2021

                            Lead Product(s) : Methylbenzylamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : AriBio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Anixa Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cleveland Clinic Launches First-of-its-Kind Preventive Breast Cancer Vaccine Study

                            Details : The investigational vaccine targets a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues but is present in the majority of triple-negative breast cancers.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Anixa Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYTO-200

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II/ Phase III

                            Recipient : Cytocom

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.

                            Details : Combined public entity to develop and commercialize next-generation immune therapies like CYTO-200, that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions.

                            Brand Name : CYTO-200

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 17, 2021

                            Lead Product(s) : CYTO-200

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Cytocom

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cleveland Clinic

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cleveland Clinic Research Shows that Melatonin is a Promising Candidate for Prevention and Treatment of COVID-...

                            Details : Results from a new Cleveland Clinic-led study suggest that melatonin, a hormone that regulates the sleep-wake cycle and is commonly used as an over-the-counter sleep aid, may be a viable treatment option for COVID-19.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 13, 2020

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth